Dresler C M, Ritter J H, Wick M R, Roper C L, Patterson G A, Cooper J D
Division of Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Ann Thorac Surg. 1995 May;59(5):1069-73. doi: 10.1016/0003-4975(95)00031-f.
Recent reports have suggested that the retention of blood group antigen expression on tumor cells may be an important prognostic factor for survival. From 1986 to 1991, 136 patients underwent operative resection for their T1 N0 non-small cell lung carcinoma. One hundred twenty tissue blocks were available for antigen testing, and the histologic types were as follows: adenocarcinoma (73 patients), squamous cell (39 patients), large cell/undifferentiated (7 patients), and mucoepidermoid (1 patient). Follow-up is complete for all patients (mean, 41 months). This distribution of patients among the blood groups was as follows: A, 56 (47%); O, 53 (44%); B, 9 (7.5%), and AB, 2 (1.7%). Immunostaining was performed for A, B, and H blood group antigens. The 5-year actuarial survival in the blood group A patients (53%) did not differ significantly from that in the blood group O patients (59%). Similarly, when tumors were examined for their respective antigens, no significant differences were found in the 5-year survival of either blood group A or O patients between the tumors that retain and those that lose blood group antigen expression. Retention or loss of blood groups A or O antigen expression does not predict survival in patients with early-stage lung carcinomas.
最近的报告表明,肿瘤细胞上血型抗原表达的保留可能是一个重要的生存预后因素。1986年至1991年,136例患者因T1 N0非小细胞肺癌接受了手术切除。有120个组织块可用于抗原检测,组织学类型如下:腺癌(73例)、鳞状细胞癌(39例)、大细胞/未分化癌(7例)和黏液表皮样癌(1例)。所有患者均完成随访(平均41个月)。患者在血型中的分布如下:A,56例(47%);O,53例(44%);B,9例(7.5%),AB,2例(1.7%)。对A、B和H血型抗原进行免疫染色。A血型患者的5年精算生存率(53%)与O血型患者(59%)无显著差异。同样,当检查肿瘤的各自抗原时,在保留和丧失血型抗原表达的肿瘤中,A血型或O血型患者的5年生存率均未发现显著差异。A或O血型抗原表达的保留或丧失不能预测早期肺癌患者的生存情况。